|1.||Asmar, R: 5 articles (01/2009 - 11/2000)|
|2.||Michelson, E L: 5 articles (07/2001 - 04/2000)|
|3.||Trenkwalder, P: 4 articles (01/2005 - 01/2000)|
|4.||Matsuoka, H: 4 articles (10/2001 - 01/2001)|
|5.||Kobayashi, N: 4 articles (10/2001 - 01/2001)|
|6.||Widdop, Robert E: 3 articles (01/2012 - 05/2003)|
|7.||Bramlage, Peter: 3 articles (01/2011 - 01/2009)|
|8.||Bönner, Gerd: 3 articles (01/2011 - 05/2004)|
|9.||Sugaya, Takeshi: 3 articles (10/2005 - 03/2002)|
|10.||Salvetti, Massimo: 3 articles (04/2005 - 11/2002)|
|1.||Hypertension (High Blood Pressure)
06/01/2001 - "Thus, candesartan cilexetil either alone or as add-on therapy was highly effective for the control of systolic or diastolic hypertension regardless of demographic background when used in typical clinical practice settings."
10/15/1998 - "In conclusion, candesartan cilexetil administered once daily effectively reduces BP in a dose-related manner while maintaining safety and tolerability; doses of 16 and 32 mg are most effective for treatment of hypertension."
01/01/2001 - "Thus, the new fixed-dose AT1-receptor blocker/diuretic combination, candesartan cilexetil-HCT 16/12.5 mg combines enhanced efficacy with excellent tolerability and sets a new standard for the treatment of hypertension requiring more than monotherapy."
01/01/2010 - "Therapy with candesartan cilexetil 0.05, 0.20, and 0.40 mg/kg/day for 4 weeks was effective in the treatment of hypertension in children aged 1 to <6 years, inducing significant dose-dependent reductions from baseline in sitting SBP (SSBP) [primary endpoint] and sitting DBP (SDBP) in the double-blind phase of a randomized, parallel-group, multinational, dose-ranging clinical study. "
01/01/2002 - "The efficacy of candesartan cilexetil is not affected by age, and the drug provided significant BP reductions in Black patients and in those with severe hypertension. "
01/01/2004 - "ARCH-J study showed that candesartan cilexetil, 8 mg/day, significantly improved the progression of heart failure when compared with placebo."
01/01/2000 - "Initial clinical studies have indicated that candesartan cilexetil is well tolerated and effective in patients with heart failure. "
01/01/2000 - "Administration of candesartan cilexetil reduces cardiac preload and afterload and is expected to be useful for the treatment of congestive heart failure."
10/01/2003 - "This 6-month study examined the safety and efficacy of candesartan cilexetil, 8 mg once daily, to prevent the progression of congestive heart failure (CHF). "
01/01/2005 - "Candesartan cilexetil: a review of its use in the management of chronic heart failure."
01/01/2006 - "The use of candesartan cilexetil as part of antihypertensive therapy in elderly patients with elevated blood pressure was also deemed to be cost effective in a Swedish analysis, primarily resulting from a reduced risk of nonfatal stroke (as shown in the SCOPE study); however, the generalisability of results to other contexts has not been established. "
09/01/2011 - "Candesartan cilexetil in the management of blood pressure for acute and recurrent stroke in Japan: the Challenge-Stroke study."
07/01/2003 - "The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) study was designed to assess the safety of modest blood pressure reduction by candesartan cilexetil in the early treatment of stroke. "
07/01/2003 - "The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors."
04/01/2004 - "Acute candesartan cilexetil therapy in stroke survivors."
02/01/2009 - "Surprisingly, the degree of cardiac fibrosis in candesartan cilexetil-treated SDT rats was less than that of SD rats. "
09/01/2003 - "Candesartan cilexetil treatment significantly reduced the fibrosis development. "
05/01/2000 - "Experiments were conducted to determine the effects of ET(A) receptor antagonism (A-127722) and AT(1) receptor antagonism (candesartan cilexetil) on the development of renal fibrosis and the decline of renal function. "
01/01/1994 - "We investigated the preventive effect of an AII receptor antagonist, TCV-116, on the development of cardiac hypertrophy and fibrosis in spontaneously hypertensive rats (SHR) at 24 weeks of age through histopathological study and an AII receptor assay. "
12/01/1997 - "Stroke-prone spontaneously hypertensive rats were given candesartan cilexetil, a specific non-peptide AT1-receptor antagonist, for 10 weeks, and cardiac phenotypic and fibrosis-related gene expression and aortic and mesenteric arterial gene expressions were determined. "
|5.||Cardiomegaly (Heart Hypertrophy)
10/01/1997 - "Another AT1 receptor antagonist, candesartan cilexetil (1 or 3 mg/kg/day for 2 weeks), also prevented this type of cardiac hypertrophy. "
04/01/1996 - "AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats."
12/01/1995 - "TCV-116 also suppressed cardiac hypertrophy. "
01/01/1994 - "We conclude that TCV-116 can prevent neointimal formation after balloon injury as well as reducing blood pressure and preventing cardiac hypertrophy."
10/01/1998 - "These findings suggest that candesartan cilexetil 2-8 mg/day orally for 8-12 weeks is beneficial in the regression of cardiac hypertrophy in patients with essential hypertension."
|3.||candesartan cilexetil (Amias)
|4.||Collagen Type I (Type I Collagen)
|7.||Messenger RNA (mRNA)
|9.||Type 1 Angiotensin Receptor
|1.||Homologous Transplantation (Allograft)
|4.||Renal Dialysis (Hemodialysis)